These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 39330016)

  • 1. Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Systematic Review of the Literature in the Last 20 Years.
    Bucuri CE; Ciortea R; Malutan AM; Oprea V; Toma M; Roman MP; Ormindean CM; Nati I; Suciu V; Mihu D
    Curr Oncol; 2024 Sep; 31(9):5242-5254. PubMed ID: 39330016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases.
    Ip PP; Cheung AN; Clement PB
    Am J Surg Pathol; 2009 Jul; 33(7):992-1005. PubMed ID: 19417585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions.
    Croce S; Ribeiro A; Brulard C; Noel JC; Amant F; Stoeckle E; Devouassoux-Shisheborah M; Floquet A; Arnould L; Guyon F; Mishellany F; Garbay D; Cuppens T; Zikan M; Leroux A; Frouin E; Duvillard P; Terrier P; Farre I; Valo I; MacGrogan GM; Chibon F
    Mod Pathol; 2015 Jul; 28(7):1001-10. PubMed ID: 25932961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors.
    Ünver NU; Acikalin MF; Öner Ü; Ciftci E; Ozalp SS; Colak E
    Arch Gynecol Obstet; 2011 Aug; 284(2):483-90. PubMed ID: 20878171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
    O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
    Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): pathology, follow-up and recurrence.
    Dall'Asta A; Gizzo S; Musarò A; Quaranta M; Noventa M; Migliavacca C; Sozzi G; Monica M; Mautone D; Berretta R
    Int J Clin Exp Pathol; 2014; 7(11):8136-42. PubMed ID: 25550862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stanford parameters stratify the risk of recurrence in gynecologic smooth muscle tumors of uncertain malignant potential.
    Travaglino A; Raffone A; Gencarelli A; Caldarelli C; Granata M; Santoro A; Zannoni GF; Mollo A; Zullo F; Insabato L
    APMIS; 2021 Jun; 129(6):283-290. PubMed ID: 33786917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors.
    Croce S; Ducoulombier A; Ribeiro A; Lesluyes T; Noel JC; Amant F; Guillou L; Stoeckle E; Devouassoux-Shisheboran M; Penel N; Floquet A; Arnould L; Guyon F; Mishellany F; Chakiba C; Cuppens T; Zikan M; Leroux A; Frouin E; Farre I; Genestie C; Valo I; MacGrogan G; Chibon F
    Mod Pathol; 2018 May; 31(5):816-828. PubMed ID: 29327710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P16, Ki67, P53, and WT1 Expression in Uterine Smooth Muscle Tumors: An Adjunct in Confirming the Diagnosis of Malignancy in Ambiguous Cases.
    Delgado B; Dreiher J; Braiman D; Meirovitz M; Shaco-Levy R
    Int J Gynecol Pathol; 2021 May; 40(3):257-262. PubMed ID: 32897968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of allelic loss as an adjuvant tool in evaluation of malignancy in uterine smooth muscle tumors.
    Esposito NN; Hunt JL; Bakker A; Jones MW
    Am J Surg Pathol; 2006 Jan; 30(1):97-103. PubMed ID: 16330948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic and Epigenomic Profile of Uterine Smooth Muscle Tumors of Uncertain Malignant Potential (STUMPs) Revealed Similarities and Differences with Leiomyomas and Leiomyosarcomas.
    Conconi D; Redaelli S; Lissoni AA; Cilibrasi C; Perego P; Gautiero E; Sala E; Paderno M; Dalprà L; Landoni F; Lavitrano M; Roversi G; Bentivegna A
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33557274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Clinicopathological Study of 21 Cases With Uterine Smooth Muscle Tumors of Uncertain Malignant Potential: Centralized Review Can Purify the Diagnosis.
    Basaran D; Usubutun A; Salman MC; Narin MA; Boyraz G; Turkmen O; Comert Kimyon G; Karalok A; Bulbul D; Turan T; Ozgul N; Yuce K
    Int J Gynecol Cancer; 2018 Feb; 28(2):233-240. PubMed ID: 29303932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Comprehensive Multidisciplinary Update.
    Tinelli A; D'Oria O; Civino E; Morciano A; Hashmi AA; Baldini GM; Stefanovic R; Malvasi A; Pecorella G
    Medicina (Kaunas); 2023 Jul; 59(8):. PubMed ID: 37629661
    [No Abstract]   [Full Text] [Related]  

  • 14. A clinicopathologic study of uterine smooth muscle tumours of uncertain malignant potential (STUMP).
    Ng JS; Han A; Chew SH; Low J
    Ann Acad Med Singap; 2010 Aug; 39(8):625-8. PubMed ID: 20838704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uterine smooth muscle tumors of uncertain malignant potential: analysis of diagnoses and therapies illustrated by two case reports.
    Peeters N; Hulsbosch S; Ballaux F; Baekelandt J
    Eur J Gynaecol Oncol; 2016; 37(3):367-73. PubMed ID: 27352566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53, p16 and ki67 as immunohistochemical prognostic markers in uterine smooth muscle tumors of uncertain malignant potential (STUMP).
    Travaglino A; Raffone A; Gencarelli A; Neola D; Oliviero DA; Alfano R; Campanino MR; Cariati F; Zullo F; Mollo A; Insabato L
    Pathol Res Pract; 2021 Oct; 226():153592. PubMed ID: 34481212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. POTENTIAL LIFE PROGNOSTIC MARKER FOR MESENCHYMAL TUMOR RESEMBLING UTERINE LEIOMYOSARCOMA.
    Nishikawa S; Hayashi T; Uzaki T; Yaegashi N; Abiko K; Konishi I
    Georgian Med News; 2023 Oct; (343):119-126. PubMed ID: 38096528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mitosis-specific marker phosphohistone-H3 (PHH3) is an independent prognosticator in uterine smooth muscle tumours: an outcome-based study.
    Chow KL; Tse KY; Cheung CL; Wong KW; Cheung AN; Wong RW; Chan AN; Yuen NW; Ngan HY; Ip PP
    Histopathology; 2017 Apr; 70(5):746-755. PubMed ID: 27864989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uterine smooth muscle tumors of uncertain malignant potential and atypical leiomyoma: a morphological study of these grey zones with clinical correlation.
    Deodhar KK; Goyal P; Rekhi B; Menon S; Maheshwari A; Kerkar R; Tongaonkar HB
    Indian J Pathol Microbiol; 2011; 54(4):706-11. PubMed ID: 22234095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical analysis in the diagnosis of uterine myometrial smooth muscle tumors.
    Stănescu AD; Nistor E; Sajin M; Stepan AE
    Rom J Morphol Embryol; 2014; 55(3 Suppl):1129-36. PubMed ID: 25607395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.